Acepodia, Inc. (TPEX:6976)

Taiwan flag Taiwan · Delayed Price · Currency is TWD
18.50
+0.10 (0.54%)
Apr 2, 2025, 1:41 PM CST
-34.86%
Market Cap 10.56B
Revenue (ttm) 427.00K
Net Income (ttm) -496.75M
Shares Out 573.68M
EPS (ttm) -0.87
PE Ratio n/a
Forward PE n/a
Dividend n/a
Ex-Dividend Date n/a
Volume 71,056
Average Volume 565,607
Open 18.60
Previous Close 18.40
Day's Range 18.35 - 18.65
52-Week Range 17.00 - 29.60
Beta n/a
RSI 22.70
Earnings Date Mar 26, 2025

About Acepodia

Acepodia, Inc. operates as a clinical stage biotechnology company. The company engages in developing cell therapies with its antibody cell conjugation (ACC) platform technology to address cancer care. It links tumor targeting antibodies to its proprietary immune cells, such as gamma delta 2 T cells to create novel ACE therapies. In addition, the company develops ACE 1831 targeting CD20 that is in phase 1 clinical trial; ACE 2016 targeting EGFR, which is in preclinical study; ACE1708; and ACE1702 targeting HER2 that is in phase 1 clinical trial.... [Read more]

Industry Biotechnology
Sector Healthcare
CEO Shih-Chia Hsiao
Country Cayman Islands
Stock Exchange Taipei Exchange
Ticker Symbol 6976
Full Company Profile

Financial Performance

In 2024, Acepodia's revenue was 427,000, a decrease of -97.43% compared to the previous year's 16.59 million. Losses were -496.75 million, -39.22% less than in 2023.

Financial Statements

News

There is no news available yet.